Here, CHIP mutations are found to disrupt degradation of phosphodiesterase PDE9A, with the CHIP-PDE9A interaction representing a potential therapeutic target for restoring cerebellar neuronal function and preventing degeneration in CHIP-related ataxia. Here, STUB1 is linked to Ataxia.